The latest news on psilocybin legislation, decriminalization efforts, and regulatory changes across the United States and worldwide.
Use these updates as a starting point for understanding state-level access, not as legal advice. For current state rules, compare the legal status hub, the Oregon access guide, and the Colorado access guide.
If you are deciding where supervised services may be practical, start with Oregon vs Colorado psilocybin therapy and then review medication and safety screening in the drug interactions guide.
Watch for three details in every legal story: whether the rule covers personal possession, supervised services, or clinical research; whether local rules differ from state rules; and whether access requires a licensed facilitator. When a law changes, also review psychedelic churches and retreat options because listings can shift as new programs open or tighten compliance.
For practical planning, save the source agency page, note the effective date, and check whether the update changes possession risk, service access, travel options, or only administrative rules.
7 posts in Legal Updates
Chacruna Institute just marked ten years of Indigenous-centred psychedelic advocacy. That lane has produced real federal wins for ayahuasca and, by GAO's count, exactly nothing for psilocybin. Here is what each track has actually delivered, and which one you can lawfully use today.
A promo for a $20 after-party in Silver Spring is not the story. The story is the hearing it followed: FDA's first broad public session on how a legal psilocybin medicine would actually be delivered, held while Compass Pathways races to finish a rolling NDA — and while a JAMA Psychiatry review says the trials underneath all of it are functionally unblinded.
At FDA's September 14, 2026 public hearing on psychedelics, a chronic-pain advocate argued that the non-drug parts of a session — touch, neuromodulation, physical therapy — are doing real work, and that pain deserves a seat at a table FDA has set for psychiatry. The argument is reasonable. The evidence base under it is one case report, three tiny trials, a null result against active placebo, and a mouse study.
Two years after the Complete Response Letter, the company formerly known as Lykos has resubmitted MDMA-assisted therapy for PTSD — and it did not run the new Phase 3 trial the FDA recommended. It is leaning on third-party data, a fresh safety study, and a friendlier regulatory climate instead.
In one week the VA launched a five-site COMP360 trial for veterans, FDA finalized psychedelic clinical-investigation guidance and set a September 14 hearing, and ICON hired Anthropic’s Claude for trial operations.
New regulations allow more service centers to open statewide, making legal psilocybin therapy accessible to thousands more residents.
Following voter approval, licensed psilocybin healing centers begin welcoming clients in Denver and Boulder.